LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys-Reference-Cited by-同舟云学术

LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys

Published:2013-06-18 Issue:6 Volume:8 Page:e65763
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Adams Andrew C.,Halstead Carolyn A.,Hansen Barbara C.,Irizarry Armando R.,Martin Jennifer A.,Myers Sharon R.,Reynolds Vincent L.,Smith Holly W.,Wroblewski Victor J.,Kharitonenkov Alexei

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference23 articles.

1. Metabolic disease drug discovery- “hitting the target” is easier said than done;DE Moller;Cell Metab,2012

2. Emerging therapies in the treatment of ‘diabesity’: beyond GLP-1;G Tharakan;Trends Pharmacol Sci,2011

3. Identification of a novel FGF, FGF-21, preferentially expressed in the liver;T Nishimura;Biochim Biophys Acta,2000

4. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models–association with liver and adipose tissue effects;J Xu;Am J Physiol Endocrinol Metab,2009

5. Fibroblast growth factor 21: from pharmacology to physiology;SA Kliewer;Am J Clin Nutr,2010

Cited by 156 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endocrine fibroblast growth factors in domestic animals;Domestic Animal Endocrinology;2024-10

2. Development of Zalfermin, a Long-Acting Proteolytically Stabilized FGF21 Analog;Journal of Medicinal Chemistry;2024-07-16

3. Potential of FGF21 in type 2 diabetes mellitus treatment based on untargeted metabolomics;Biochemical Pharmacology;2024-07

4. Improving Downstream Process Related Manufacturability Based on Protein Engineering—A Feasibility Study;Engineering in Life Sciences;2024-06-28

5. Defective FGFR1 Signaling Disrupts Glucose Regulation: Evidence From Humans With FGFR1 Mutations;Journal of the Endocrine Society;2024-06-13